CLAIM #43277 · Merck & Company Inc (MRK) · 2023Q1 earnings call · Apr 27, 2023 · due Dec 31, 2023
“We are planning to initiate Phase 3 studies of MK-5684, a novel oral, nonsteroidal inhibitor of CYP-11A1, from our collaboration with Orion, by the end of this year.”
Dean Li · President, Merck Research Labs
CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
We are planning to initiate Phase 3 studies of MK-5684... by the end of this year.
Reported
MK-5684, our CYP11A1 inhibitor in collaboration with Orion in metastatic castrate-resistant prostate cancer
Verify independently
SEC filings for MRK ↗ · Claim quote is verbatim from the 2023Q1 earnings call.